This meta-analysis confirms that SGLT2 inhibitors alleviate symptom burden in individuals with HFrEF, HFpEF, and HFmrEF while lowering cardiovascular mortality, heart failure hospitalization, and renal disease progression. This evidence concerns the gene SLC5A2 and heart failure.